Firebrick Pharma Limited engages in the development and partnering of broad-spectrum antimicrobial spray for the treatment of common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.04411864521821761 | N/A |
Market Cap | $7.86M | N/A |
Shares Outstanding | 178.05M | 52.80% |
Employees | 0 | N/A |
Shareholder Equity | 2.48M | -70.09% |
Valuation | 2023 | Change |
---|---|---|
P/S Ratio | 13943.44 | N/A |
P/B Ratio | 3.17 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -1.8646 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $563.36 | N/A |
Earnings | -$4.62M | N/A |
Gross Margin | 1.00 | N/A |
Operating Margin | -8.27K | N/A |
Net income margin | -8.20K | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $2.02M | N/A |
Cash on Hand | $1.60M | N/A |
Debt to Equity | 0.1388 | 276.24% |
Current Ratio | $5.11 | -72.37% |